Patents by Inventor Christopher Chadwick

Christopher Chadwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060155118
    Abstract: This invention pertains to the use of a novel set of tags for the immobilization and/or purification of proteins or other biological or organic molecules. The invention provides troponin C, troponin C binding peptide, and troponin I, or active fragments or analogues thereof as convenient tags and affinity ligands for immobilizing, attaching, or purifying proteins or other molecules. Methods for producing troponin-tagged molecules, such as recombinant fusion proteins, are described. Methods for preparing a troponin affinity matrix that is capable of specifically binding its cognate ligand in the presence of calcium, and methods for using such a matrix to purify troponin-tagged molecules are also described.
    Type: Application
    Filed: March 6, 2006
    Publication date: July 13, 2006
    Applicant: Aristex, Inc.
    Inventors: Randolph Moeckli, Christopher Chadwick
  • Publication number: 20060111421
    Abstract: The present invention concerns a method of treatment or prevention of myocardial ischemia-reperfusion injury by diagnosing that a person is in need of treatment or prevention of myocardial ischemia-reperfusion injury and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
    Type: Application
    Filed: August 17, 2005
    Publication date: May 25, 2006
    Applicant: Wyeth
    Inventors: Christopher Chadwick, Douglas Harnish
  • Publication number: 20050240511
    Abstract: An investment system for projects seeking funding, such as pre-trading enterprises, is disclosed. The system comprises a share allocation facility for allocating shares to a project on the basis of the funding that they require, and a stock exchange for trading shares in the project. During development of the project, the project is required to meet a number of development goals, and its progress through each of the development goals is audited. The results of the audit are published and may affect the share price in the project.
    Type: Application
    Filed: September 14, 2004
    Publication date: October 27, 2005
    Inventors: Christopher Chadwick, Raglan Andrew Harold Tribe
  • Publication number: 20050119324
    Abstract: The present invention concerns a method of treating atherosclerosis by diagnosing that a person is in need of treatment for atherosclerosis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
    Type: Application
    Filed: September 23, 2004
    Publication date: June 2, 2005
    Applicant: Wyeth
    Inventors: Douglas Harnish, Christopher Chadwick
  • Publication number: 20050119276
    Abstract: The present invention concerns a method of treating inflammatory bowel disease by diagnosing that a person is in need of treatment for inflammatory bowel disease and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
    Type: Application
    Filed: September 23, 2004
    Publication date: June 2, 2005
    Applicant: Wyeth
    Inventors: Douglas Harnish, Christopher Chadwick, James Keith
  • Publication number: 20050113405
    Abstract: The present invention concerns a method of treating rheumatoid arthritis by diagnosing that a person is in need of treatment for rheumatoid arthritis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain embodiments, the administration is with a substantial absence of uterotropic activity.
    Type: Application
    Filed: September 23, 2004
    Publication date: May 26, 2005
    Applicant: Wyeth
    Inventors: Douglas Harnish, Christopher Chadwick, James Keith
  • Publication number: 20050043510
    Abstract: This invention pertains to the use of a novel set of tags for the immobilization and/or purification of proteins or other biological or organic molecules. The invention provides troponin C, troponin C binding peptide, and troponin I, or active fragments or analogues thereof as convenient tags and affinity ligands for immobilizing, attaching, or purifying proteins or other molecules. Methods for producing troponin-tagged molecules, such as recombinant fusion proteins, are described. Methods for preparing a troponin affinity matrix that is capable of specifically binding its cognate ligand in the presence of calcium, and methods for using such a matrix to purify troponin-tagged molecules are also described.
    Type: Application
    Filed: April 7, 2004
    Publication date: February 24, 2005
    Inventors: Randolph Moeckli, Christopher Chadwick